Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients
Tóm tắt
This study aimed to investigate the outcome of patients with advanced gastrointestinal stromal tumors (GISTs) exhibiting focal disease progression during imatinib therapy, treated by surgical resection and imatinib continuation. A consecutive series of 38 patients with metastatic GISTs who underwent treatment with imatinib at our centers during a defined period of time was evaluated. Patients were evaluated for demographics including tumor-related features, initial response, disease recurrence, and salvage treatment modalities, and were classified as having either focal or generalized progression upon presentation prior to salvage therapy. After a median follow-up of 31.8 months, 25 of the 38 (65.8%) patients had progressed. Nine (36%) patients were classified as having focal and 16 (64%) as having generalized progression. Salvage therapies were: surgical resection and imatinib dose escalation in patients exhibiting focal progression and imatinib dose escalation alone in the majority of patients exhibiting generalized progression. Focal progression was associated with prolonged progression-free survival (PFS) and overall survival (OS) after salvage therapy as compared with generalized progression (median PFS and OS, 11.3 months and not attained, versus 2.5 and 22.8 months, respectively). Six-month PFS was 89% and 39% in patients exhibiting focal and generalized progression, respectively. KIT mutation analysis of controlled and progressive lesions was performed in 4 patients with focal progression. Secondary KIT mutations affected progressive lesions, whereas nonprogressive lesions harbored the original mutations only. Patients with advanced GIST exhibiting focal disease progression during imatinib therapy may benefit from surgical resection and imatinib continuation. Imatinib resistance seems to be partial in these patients.
Tài liệu tham khảo
S George J Desai (2002) ArticleTitleManagement of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors Curr Treat Options Oncol 3 489–96 Occurrence Handle12392638 Occurrence Handle10.1007/s11864-002-0068-2
S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro et al. (1998) ArticleTitleGain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577–80 Occurrence Handle9438854 Occurrence Handle10.1126/science.279.5350.577 Occurrence Handle1:CAS:528:DyaK1cXotVyhsw%3D%3D
CL Corless JA Fletcher MC Heinrich (2004) ArticleTitleBiology of gastrointestinal stromal tumors J Clin Oncol 22 3813–25 Occurrence Handle15365079 Occurrence Handle10.1200/JCO.2004.05.140 Occurrence Handle1:CAS:528:DC%2BD2cXhtVCitb%2FL
CL Corless A Schroeder D Griffith A Town L McGreevey P Harrell (2005) ArticleTitlePDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 5357–64 Occurrence Handle15928335 Occurrence Handle10.1200/JCO.2005.14.068 Occurrence Handle1:CAS:528:DC%2BD2MXpslOrtLY%3D
GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts (2002) ArticleTitleEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472–80 Occurrence Handle12181401 Occurrence Handle10.1056/NEJMoa020461 Occurrence Handle1:CAS:528:DC%2BD38XmtV2nt7s%3D
RP Dematteo MC Heinrich WM El-Rifai G Demetri (2002) ArticleTitleClinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466–77 Occurrence Handle12094371 Occurrence Handle10.1053/hupa.2002.124122 Occurrence Handle1:CAS:528:DC%2BD38XlslCls7o%3D
LL Chen JC Trent EF Wu GN Fuller L Ramdas W Zhang (2004) ArticleTitleA missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 913–9
JY Blay S Bonvalot P Casali H Choi M Debiec-Richter AP Dei Tos (2005) ArticleTitleConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16 566–78 Occurrence Handle15781488 Occurrence Handle10.1093/annonc/mdi127
E Wardelmann A Hrychyk S Merkelbach-Bruse K Pauls J Goldstein P Hohenberger (2004) ArticleTitleAssociation of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors J Mol Diagn 6 197–204 Occurrence Handle15269295 Occurrence Handle1:CAS:528:DC%2BD2cXmvVWrurg%3D
M Van Glabbeke J Verweij PG Casali A Le Cesne P Hohenberger I Ray-Coquard (2005) ArticleTitleInitial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795–804 Occurrence Handle16110036 Occurrence Handle10.1200/JCO.2005.11.601 Occurrence Handle1:CAS:528:DC%2BD2MXhtVersrzF
CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski (2005) ArticleTitleAcquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182–90 Occurrence Handle15930355 Occurrence Handle10.1158/1078-0432.CCR-04-2245 Occurrence Handle1:CAS:528:DC%2BD2MXks1GksLw%3D
CP Raut M Posner J Desai JA Morgan S George D Zahrieh (2006) ArticleTitleSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325–31 Occurrence Handle16710031 Occurrence Handle10.1200/JCO.2005.05.3439 Occurrence Handle1:CAS:528:DC%2BD28XlvV2ksbw%3D
AT Van Oosterom I Judson J Verweij S Stroobants E Donato di Paola InstitutionalAuthorNameEuropean Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2001) ArticleTitleSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421–3 Occurrence Handle11705489 Occurrence Handle10.1016/S0140-6736(01)06535-7 Occurrence Handle1:CAS:528:DC%2BD3MXot1Ojtb0%3D
J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay (2004) ArticleTitleProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127–34 Occurrence Handle15451219 Occurrence Handle10.1016/S0140-6736(04)17098-0 Occurrence Handle1:CAS:528:DC%2BD2cXnvVOiu7o%3D
JR Zalcberg J Verweij PG Casali A Le Cesne P Reichardt JY Blay (2005) ArticleTitleOutcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg Eur J Cancer 1 1751–7 Occurrence Handle10.1016/j.ejca.2005.04.034
E Tamborini L Bonadiman A Greco V Albertini T Negri A Gronchi (2004) ArticleTitleA new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient Gastroenterology 127 294–9 Occurrence Handle15236194 Occurrence Handle10.1053/j.gastro.2004.02.021 Occurrence Handle1:CAS:528:DC%2BD2cXmsVShsL8%3D
E Tamborini E Gabanti MS Lagonigro T Negri S Pilotti MA Pierotti (2005) ArticleTitleKIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient Cancer Res 65 1115 Occurrence Handle15705916 Occurrence Handle1:CAS:528:DC%2BD2MXhtVWnu70%3D
E Wardelmann N Thomas S Merkelbach-Bruse K Pauls N Speidel (2005) ArticleTitleAcquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations Lancet Oncol 6 249–51 Occurrence Handle15811621 Occurrence Handle10.1016/S1470-2045(05)70097-8 Occurrence Handle1:CAS:528:DC%2BD2MXjtlWjtLY%3D